Abeona Therapeut Financials
This page shows Abeona Therapeut (ABEO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Abeona Therapeut has an operating margin of -1536.9%, meaning the company retains $-1537 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses.
Abeona Therapeut carries a low D/E ratio of 0.05, meaning only $0.05 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 6.93, Abeona Therapeut holds $6.93 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Abeona Therapeut generated -$76.3M in operating cash flow, capex of $8.0M consumed most of it, leaving -$84.3M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Abeona Therapeut earns a strong 44.7% return on equity (ROE), meaning it generates $45 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is up from -144.8% the prior year.
Abeona Therapeut passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Abeona Therapeut generates $-1.07 in operating cash flow (-$76.3M OCF vs $71.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Abeona Therapeut earns $-23.9 in operating income for every $1 of interest expense (-$89.4M vs $3.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Abeona Therapeut generated $5.8M in revenue in fiscal year 2025.
Abeona Therapeut's EBITDA was -$86.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 39.7% from the prior year.
Abeona Therapeut reported $71.2M in net income in fiscal year 2025. This represents an increase of 211.7% from the prior year.
Abeona Therapeut earned $1.01 per diluted share (EPS) in fiscal year 2025. This represents an increase of 165.2% from the prior year.
Cash & Balance Sheet
Abeona Therapeut generated -$84.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 44.2% from the prior year.
Abeona Therapeut held $78.4M in cash against $7.8M in long-term debt as of fiscal year 2025.
Abeona Therapeut had 55M shares outstanding in fiscal year 2025. This represents an increase of 20.6% from the prior year.
Margins & Returns
Abeona Therapeut's gross margin was 73.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
Abeona Therapeut's operating margin was -1536.9% in fiscal year 2025, reflecting core business profitability.
Abeona Therapeut's net profit margin was 1223.1% in fiscal year 2025, showing the share of revenue converted to profit.
Abeona Therapeut's ROE was 44.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 189.5 percentage points from the prior year.
Capital Allocation
Abeona Therapeut invested $26.8M in research and development in fiscal year 2025. This represents a decrease of 22.0% from the prior year.
Abeona Therapeut invested $8.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 226.0% from the prior year.
ABEO Income Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | $400K | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | $488K | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $4.2M-29.1% | $5.9M-40.2% | $9.9M | N/A | $8.9M-3.0% | $9.2M+27.9% | $7.2M |
| SG&A Expenses | N/A | $19.3M+12.6% | $17.1M+75.2% | $9.8M | N/A | $6.4M-25.9% | $8.6M+21.4% | $7.1M |
| Operating Income | N/A | -$24.0M-5.4% | -$22.8M-15.5% | -$19.7M | N/A | -$15.3M+14.1% | -$17.9M-24.7% | -$14.3M |
| Interest Expense | N/A | $901K-5.9% | $957K-4.1% | $998K | N/A | $1.1M+2.8% | $1.1M+12.6% | $952K |
| Income Tax | N/A | -$15.2M-198.0% | $15.5M | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | -$5.2M-104.7% | $108.8M+1004.8% | -$12.0M | N/A | -$30.3M-508.7% | $7.4M+123.5% | -$31.6M |
| EPS (Diluted) | N/A | $-0.10-105.8% | $1.71+812.5% | $-0.24 | N/A | $-0.63-142.3% | $-0.26+77.6% | $-1.16 |
ABEO Balance Sheet
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $219.6M-5.0% | $231.1M-6.1% | $246.2M+147.8% | $99.4M-8.8% | $108.9M-9.7% | $120.6M-10.0% | $134.0M+79.1% | $74.8M |
| Current Assets | $204.9M-5.2% | $216.1M-6.9% | $232.3M+163.6% | $88.1M-12.6% | $100.9M-10.5% | $112.7M-10.5% | $125.9M+88.7% | $66.7M |
| Cash & Equivalents | $78.4M-5.4% | $82.9M-49.3% | $163.5M+926.2% | $15.9M-31.8% | $23.4M+48.5% | $15.7M-54.3% | $34.4M+96.1% | $17.6M |
| Inventory | $5.5M+13.3% | $4.8M+80.6% | $2.7M | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $6.1M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $60.4M+0.8% | $59.9M-27.6% | $82.7M+42.6% | $58.0M-10.7% | $64.9M-13.3% | $74.8M+23.1% | $60.8M-27.4% | $83.7M |
| Current Liabilities | $29.6M+33.3% | $22.2M-35.7% | $34.5M+91.9% | $18.0M+8.4% | $16.6M-10.0% | $18.4M+9.4% | $16.8M+41.7% | $11.9M |
| Long-Term Debt | $7.8M-28.1% | $10.9M-22.4% | $14.0M+25.7% | $11.1M-14.6% | $13.0M-8.2% | $14.2M-11.9% | $16.1M-10.8% | $18.1M |
| Total Equity | $159.2M-7.0% | $171.2M+4.7% | $163.6M+295.1% | $41.4M-6.0% | $44.0M-3.8% | $45.8M-37.5% | $73.2M+924.7% | -$8.9M |
| Retained Earnings | -$742.1M-2.8% | -$721.6M-0.7% | -$716.5M+13.2% | -$825.3M-1.5% | -$813.3M-1.2% | -$804.0M-3.9% | -$773.7M+0.9% | -$781.1M |
ABEO Cash Flow Statement
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$18.0M+15.3% | -$21.2M-12.8% | -$18.8M-2.1% | -$18.4M-11.1% | -$16.6M-35.4% | -$12.2M+3.5% | -$12.7M+12.8% | -$14.5M |
| Capital Expenditures | $1.2M-54.2% | $2.5M-13.1% | $2.9M+107.1% | $1.4M+131.2% | $606K+50.0% | $404K-43.2% | $711K-1.9% | $725K |
| Free Cash Flow | -$19.1M+19.4% | -$23.7M-9.3% | -$21.7M-9.5% | -$19.8M-15.4% | -$17.2M-35.8% | -$12.6M+5.7% | -$13.4M+12.2% | -$15.3M |
| Investing Cash Flow | $9.6M+114.8% | -$64.6M-141.5% | $155.9M+3600.2% | $4.2M-77.7% | $18.9M+406.1% | -$6.2M+86.0% | -$44.1M-464.6% | -$7.8M |
| Financing Cash Flow | $3.6M-30.0% | $5.2M-50.8% | $10.5M+55.1% | $6.8M+27.4% | $5.3M+1877.3% | -$299K-100.4% | $73.7M+189.6% | $25.4M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ABEO Financial Ratios
| Metric | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | -5698.0% | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | 27208.3% | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -3.0%-69.5pp | 66.5%+95.6pp | -29.1% | N/A | -66.1%-76.2pp | 10.1% | N/A |
| Return on Assets | N/A | -2.2%-46.4pp | 44.2%+56.3pp | -12.1% | N/A | -25.1%-30.6pp | 5.5%+47.7pp | -42.2% |
| Current Ratio | 6.93-2.8 | 9.74+3.0 | 6.73+1.8 | 4.90-1.2 | 6.08-0.0 | 6.12-1.4 | 7.48+1.9 | 5.61 |
| Debt-to-Equity | 0.05-0.0 | 0.06-0.0 | 0.09-0.2 | 0.27-0.0 | 0.30-0.0 | 0.31+0.1 | 0.22+2.3 | -2.04 |
| FCF Margin | N/A | N/A | -5421.3% | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Abeona Therapeut's annual revenue?
Abeona Therapeut (ABEO) reported $5.8M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Abeona Therapeut profitable?
Yes, Abeona Therapeut (ABEO) reported a net income of $71.2M in fiscal year 2025, with a net profit margin of 1223.1%.
What is Abeona Therapeut's EBITDA?
Abeona Therapeut (ABEO) had EBITDA of -$86.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Abeona Therapeut have?
As of fiscal year 2025, Abeona Therapeut (ABEO) had $78.4M in cash and equivalents against $7.8M in long-term debt.
What is Abeona Therapeut's gross margin?
Abeona Therapeut (ABEO) had a gross margin of 73.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Abeona Therapeut's operating margin?
Abeona Therapeut (ABEO) had an operating margin of -1536.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Abeona Therapeut's net profit margin?
Abeona Therapeut (ABEO) had a net profit margin of 1223.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Abeona Therapeut's return on equity (ROE)?
Abeona Therapeut (ABEO) has a return on equity of 44.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Abeona Therapeut's free cash flow?
Abeona Therapeut (ABEO) generated -$84.3M in free cash flow during fiscal year 2025. This represents a -44.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Abeona Therapeut's operating cash flow?
Abeona Therapeut (ABEO) generated -$76.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Abeona Therapeut's total assets?
Abeona Therapeut (ABEO) had $219.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Abeona Therapeut's capital expenditures?
Abeona Therapeut (ABEO) invested $8.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Abeona Therapeut spend on research and development?
Abeona Therapeut (ABEO) invested $26.8M in research and development during fiscal year 2025.
What is Abeona Therapeut's current ratio?
Abeona Therapeut (ABEO) had a current ratio of 6.93 as of fiscal year 2025, which is generally considered healthy.
What is Abeona Therapeut's debt-to-equity ratio?
Abeona Therapeut (ABEO) had a debt-to-equity ratio of 0.05 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Abeona Therapeut's return on assets (ROA)?
Abeona Therapeut (ABEO) had a return on assets of 32.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Abeona Therapeut's cash runway?
Based on fiscal year 2025 data, Abeona Therapeut (ABEO) had $78.4M in cash against an annual operating cash burn of $76.3M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Abeona Therapeut's Piotroski F-Score?
Abeona Therapeut (ABEO) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Abeona Therapeut's earnings high quality?
Abeona Therapeut (ABEO) has an earnings quality ratio of -1.07x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Abeona Therapeut cover its interest payments?
Abeona Therapeut (ABEO) has an interest coverage ratio of -23.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Abeona Therapeut?
Abeona Therapeut (ABEO) scores 60 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.